Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies

  |  

References

  1. Collegium Pharmaceutical Inc. News release: Collegium announces FDA tentative approval for Xtampza ER, a novel abuse-deterrent analgesic for chronic pain. 2015 Nov 9.
  2. Genentech. New release: Genentech has announced the initiation of a phase 2 clinical trial investigating the use of obinutuzumab. 2015 Nov 2.
  3. GlaxoSmithKline. News release: GSK announces positive results from phase 3 BLISS-SC study of Benlysta (belimumab) administered subcutaneously in patients with systemic lupus erythematosus. 2015 Nov 7.
  4. McKee S. GSK’s lupus drug Benlysta hits PhIII targets. PharmaTimes. 2015 Nov 9.

Related Articles

    FDA Approves New Drugs for Pain

    FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

    Lupus Nephritis: Understanding the Paradigm for Treatment

    ACR BEYOND LIVE—Among patients with systemic lupus erythematosus (SLE), lupus nephritis remains one of the leading causes of mortality, and patients with both SLE and end-stage renal disease demonstrate standardized mortality ratios higher than 60 times that of patients with SLE who have normal kidney function.1 Although the ACR Guidelines for Screening, Treatment, and Management…

    FDA Approves Belimumab & Voclosporin for Lupus Nephritis

    In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.